Risk factors
Galectin Therapeutics (GALT) risk factors
Item 1A of every Galectin Therapeutics Inc. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.
- FY2025 10-K risk factors40 risks7 new9 dropped4 reworded
Board chairman Uihlein remains our primary debt and equity financing source through a $10 million line of credit. Net losses reached $29.7 million in 2025, with an accumulated deficit of $431 million. Belapectin's NAVIGATE trial failed its primary endpoint, and we are planning a Phase 3 trial following FDA discussions.
Filed Mar 31, 2026 - FY2024 10-K risk factors42 risks
Galectin Therapeutics faces severe going concern doubts after accumulating $354 million in deficits and burning $41.8 million in 2024 cash.
Filed Mar 31, 2025